aTyr Pharma has reached agreement with the United States Food and Drug Administration on the design of a new Phase 3 trial for efzofitimod in chronic symptomatic pulmonary sarcoidosis with restrictive lung disease, giving the program a defined route forward after its previous pivotal study missed its primary endpoint. The new global trial will shift the primary endpoint to forced vital capacity, or FVC, and focus on the patient subgroup in which post hoc analyses from the earlier EFZO-FIT study suggested a more meaningful treatment effect. Study-related activities are expected to begin in the fourth quarter, while aTyr Pharma intends to focus subsequent regulatory submissions on the United States and Europe.
The FDA alignment is an important regulatory recovery for a program that faced substantial uncertainty after EFZO-FIT failed to demonstrate a statistically significant reduction in oral corticosteroid use. It does not erase the risk created by that earlier miss, however, because the new Phase 3 study is effectively testing whether a narrower patient population and a different clinically meaningful endpoint can convert encouraging subgroup observations into prospective evidence strong enough for approval.
New efzofitimod Phase 3 trial shifts attention from steroid reduction to preservation of lung function
The planned Phase 3 trial will enroll up to approximately 372 patients with chronic symptomatic pulmonary sarcoidosis and restrictive lung disease. Participants are expected to receive either 5.0 mg/kg efzofitimod or placebo intravenously once every three weeks for 54 weeks, with 17 total doses administered during the study. Patients will remain on stable background treatment consisting of no more than 5 mg of daily oral corticosteroid and/or another immunosuppressive therapy.
Change from baseline in FVC at Week 48 will serve as the primary endpoint, while change in the King’s Sarcoidosis Questionnaire-Lung score will be the key secondary endpoint. The design reflects earlier FDA feedback indicating that FVC and the questionnaire provide direct measures of how patients function and feel, with aTyr Pharma ultimately selecting FVC as the more appropriate primary endpoint while additional validation work continues around the patient-reported measure.
That endpoint change is central to the new development strategy. EFZO-FIT was originally designed around corticosteroid reduction, testing whether efzofitimod could allow patients to lower chronic steroid exposure while maintaining disease control. The study failed that primary test, with mean daily corticosteroid dose falling to 2.79 mg in the 5.0 mg/kg efzofitimod arm versus 3.52 mg with placebo, a difference that was not statistically significant.
The earlier trial did generate several encouraging secondary observations. More than half of patients receiving the higher efzofitimod dose achieved complete steroid withdrawal compared with just over 40% receiving placebo, while the King’s Sarcoidosis Questionnaire-Lung score improved more strongly in the treatment arm. Because the primary endpoint failed under the trial’s hierarchical statistical plan, however, subsequent p-values were nominal and could not establish confirmatory efficacy.
The new study is therefore not simply repeating EFZO-FIT. It is using what aTyr Pharma learned from that trial to define a population in which preservation of pulmonary function may provide a clearer measure of benefit.
Restrictive lung disease subgroup now forms the basis of aTyr Pharma’s regulatory strategy
The decision to focus on patients with restrictive lung disease emerged from subsequent analyses of EFZO-FIT. aTyr Pharma reported that the subgroup demonstrated what it described as clinically meaningful benefit in FVC and improvements across several patient-reported outcomes with 5.0 mg/kg efzofitimod compared with placebo. Those observations led the company to submit the new protocol to the FDA and concentrate the next pivotal trial on this more clearly defined population.
The distinction could matter because pulmonary sarcoidosis is heterogeneous. Some patients experience relatively limited or self-resolving disease, while others develop chronic inflammation, restrictive physiology and progressive loss of lung function. aTyr Pharma is now targeting the latter group, where deterioration in FVC may provide a more measurable clinical signal and where the treatment need may be greater.
Efzofitimod is designed as a selective modulator of neuropilin-2 and originates from aTyr Pharma’s transfer RNA synthetase biology platform. The company is developing the candidate as an immunomodulatory therapy for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease.
The scientific thesis remains that efzofitimod could control inflammatory activity while reducing dependence on prolonged corticosteroid exposure. Chronic steroid treatment can be effective in sarcoidosis but may create substantial long-term tolerability problems, making steroid-sparing strategies attractive if they can also preserve respiratory function.
The next Phase 3 trial will need to establish that benefit prospectively rather than relying on a subgroup identified after the original study. Post hoc analyses can help generate a development hypothesis, but patient selection based on retrospective findings introduces uncertainty that only another controlled trial can resolve.
aTyr Pharma has reshaped the company around efzofitimod as cash conservation becomes critical
The regulatory alignment arrives after aTyr Pharma made significant changes to conserve capital and preserve its ability to run another late-stage trial. The company announced a roughly 60% workforce reduction and broader program prioritization in August, concentrating resources on efzofitimod in interstitial lung disease while reducing annualized operating expenses by an estimated $13 million beginning in the fourth quarter.
aTyr Pharma ended the second quarter with approximately $58.9 million in cash, cash equivalents, restricted cash and investments. Management has said the restructuring and revised operating plan should extend the company’s financial runway into late 2028 based on current operations.
That runway provides time to initiate the next Phase 3 study, but financing remains an important consideration because global pivotal trials involving several hundred patients are expensive. The company’s current market capitalization is only about $33 million, considerably below its reported second-quarter cash position, highlighting how heavily investors continue to discount efzofitimod following the earlier pivotal failure.
The broader interstitial lung disease strategy remains alive through the Phase 2 EFZO-CONNECT trial in systemic sclerosis-associated interstitial lung disease. Enrollment has been completed in that 23-patient study, with topline data expected in the first quarter of 2027. A positive result could provide additional biological validation for efzofitimod beyond pulmonary sarcoidosis, although the small proof-of-concept study is not intended to provide registration-level evidence.
The company has therefore become increasingly concentrated around a single core asset. That focus can improve capital efficiency, but it also raises the importance of every subsequent efzofitimod clinical milestone.
aTyr Pharma stock falls despite FDA alignment as investors remain cautious after EFZO-FIT
Investor reaction to the regulatory update has been notably negative despite the apparent removal of one development uncertainty. aTyr Pharma shares were trading around $0.34 in afternoon trading, down nearly 10% from the previous close of roughly $0.38, after briefly reaching about $0.41 earlier in the session. Trading volume exceeded 125 million shares, far above normal levels, indicating unusually heavy activity around the announcement.
The decline suggests that FDA agreement on trial design has not been enough to restore confidence in the program. Investors still face a lengthy development timeline, the cost of another Phase 3 study and the fundamental question of whether a signal identified retrospectively in restrictive lung disease patients can be reproduced prospectively.
The stock is also trading near the bottom of its 52-week range of approximately $0.32 to $1.12. That depressed valuation reflects the damage caused by the original EFZO-FIT miss and the dilution and financing risks generally associated with small biotechnology companies attempting to fund additional pivotal studies.
The FDA alignment nevertheless removes an important regulatory obstacle. aTyr Pharma now knows which patients it intends to study, which dose it plans to use and which primary endpoint the agency has accepted for the next pivotal test. Those decisions turn the efzofitimod story from an uncertain post-failure review into a defined clinical-development program.
The remaining question is substantially harder: whether the restrictive lung disease subgroup represents a genuinely responsive population or whether the apparent benefit was partly a consequence of retrospective analysis. The new Phase 3 study is designed to answer that question, and its eventual outcome is likely to determine both efzofitimod’s regulatory future and the longer-term direction of aTyr Pharma.
